Clinical trial · Observational
Registry of Local Recurrences After Breast-conserving Surgery
Registry of Local Recurrences After Breast-conserving Surgery in Portugal and Spain
NCT05406661CI-TRIAL-00070613R_ReLoCCnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The ReLoCC project is a prospective, multicenter, clinical study to register cases of local recurrence after breast-conserving surgery, in centers dedicated to the treatment of breast cancer, in Portugal and Spain. The comparison of the results obtained will allow the optimization of the treatment, making it increasingly personalized.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Determine prevalence of local recorrence of breast cancer after conserving surgery in Portugal and Spain
- timeFrame
- 2 years
- description
- Number of cases per year
- measure
- Follow-up of recurrences up to 5 years after treatment of first recurrence
- timeFrame
- 5 years
- description
- Number of cases per year
Secondary outcomes (4)
- measure
- Identification of risk factors for local recurrence
- timeFrame
- On inclusion time (2 years)
- description
- Frequency of risk factors
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients 2. Age \> 18 years 3. Patients who have previously undergone breast-conserving surgery as part of the treatment of invasive or non-invasive (in situ) breast cancer 1. and adjuvant breast RT: total (WBI) or partial (PBI) 2. without adjuvant radiotherapy to the breast 4. Recent histological diagnosis of homolateral, invasive or non-invasive (in situ) breast carcinoma Exclusion Criteria: 1. Male 2. Age \< 18 years 3. Stage 4 at diagnosis 4. Patients operated outside the participating Centers and for whom it is not possible to obtain complete information regarding the primary treatment 5. History of other primary invasive malignant tumor (except non-melanoma skin carcinomas) 6. Patients already treated for another local recurrence of breast carcinoma 7. Absence of clinical follow-up and records in clinical process
References
Publications (0)
Data not yet available
No reference posted for this study.